Alibaba is planning to implement a revenue-sharing model for its next Qwen open-weight AI model, targeting larger companies that use the model commercially. This approach requires these companies to reach a commercial agreement with Alibaba, similar to the model used by Moonshot for its Kimi K3 AI. The exact revenue-sharing terms have not been finalized, but this move represents a shift in how Alibaba monetizes its open-weight models. This strategy could influence other AI developers to adopt similar business models.
Read originalStanford's Evo 2 AI model has made a significant leap in synthetic biology by generating phages that effectively target E. coli. This breakthrough demonstrates the potential of AI to design entire viral genomes, moving beyond simple DNA edits. The model produced thousands of candidate genomes, with 16 showing strong E. coli-killing activity in lab tests. By releasing Evo 2 as open-source software, Stanford is inviting further exploration and innovation in genome design, potentially paving the way for new treatments against resistant bacteria like MRSA.
MIT researchers have identified a crucial challenge in AI health tools: their effectiveness varies significantly with the user's expertise. Published in Nature Medicine, the study found that non-experts improved their diagnostic accuracy with AI assistance, mainly by relying on the model's predictions. Conversely, primary care providers achieved better results when they received AI predictions without accompanying explanations, indicating that detailed explanations might not always benefit trained professionals. This research highlights the importance of designing AI interfaces that consider the user's level of expertise to mitigate automation bias and enhance diagnostic accuracy.